Suproclone is a sedative and anxiolytic drug in the cyclopyrrolone family of drugs, developed by the French pharmaceutical company Rhône-Poulenc. The mechanism of action by which Suproclone produces it's sedative and anxiolytic effects is by modulating GABAA receptors

Tabilautide (also known as RP 56142) is a tripeptide derivative patented by Rhone-Poulenc Industries S. A. as an immune adjuvant. In preclinical studies, Tabilautide displays potent protective activities against bacterial infections such as K. pneumoniae, L. monocytogenes or S. Typhimurium. Besides that Tabilautide shows antimetastatic activity and induces macrophage activation and enhanced cytotoxicity of natural killer cells in spleen, blood, and liver. These activities correlate with prophylactic and therapeutic effects of Tabilautide on artificial liver metastases of histiocytosarcoma.

Ceftiolene (42980RP) is a new cephalosporin with a broad antibacterial spectrum similar to cefotaxime or ceftriaxone. The affinities of ceftiolene for penicillin-binding proteins are very comparable with those of ceftriaxone and cefotaxime for Escherichia coli, and generally greater than those of latamoxef (moxalactam) for the higher molecular weight PBPs of E. coli. Enterobacter cloacae. The affinity of ceftiolene for PBP1 of Staphylococcus aureus is greater than those of cefotaxime or latamoxef but comparable with these antibiotics for PBP3. The bacteriolytic activity of ceftiolene at defined concentrations against Gram-negative organisms is similar to that of ceftriaxone and significantly better than that of the other third-generation cephalosporins tested.